Citations

Clear

6274 citation(s) found for "To, Andrew".

Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Holmes, DaJuanicia N. , Pieper, Karen S. , Ezekowitz, Michael D. , Fonarow, Gregg C. , Gersh, Bernard J. , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Singer, Daniel E. , Piccini, Jonathan P. , Mendelson, R. A., NEUTEL, J, Pan, Dengji, Poock, James J., Raffetto, J.D., Greengold, R., Roan, P G, Saba, F., Sackett, Melanie K., Schneider, R., Seymour, Zachary , Shanes, Jeffrey G., Smiley, Nasser, Smith, David H. , Snipes, C., Sotolongo, Rodolfo, Staniloae, Cezar , Stoltz, S., Suresh, D.P. , Tak, Tahir , Tannenbaum, A., Turk, Samir, Vora, Kishor, Randhawa, P., Zebrack, James S., Silva, Eduardo , Riley, Edward T., Weinstein, D., Vasiliauskas, Tomas, Goldbarg, Seth , Yarlagadda, Chakri, Laurion, D., Osunkoya, A., Burns, Richéal , Castor, Tatsiana , Luttman, C., Anton, Stephen D. , McGarvey, Jeremy R., Guthrie, Robert D., Deriso, George T., Flood, Raymond, Fleischer, L H, Fierstein, J.S., Jacobs, George B., Adjei, Nasser, Akyea-Djamson, Ayim, Bacon, Jenny , Bedwell, Noel W., Berger, PB, Berry, Joni I., Bhagwat, Ravi, Boccalandro, Fernando , Capó, Jaïr Dilmé, Kapadia, Sumit, Casanova, Rene, Morriss, J.E., Elsen, J., Farsad, Ramin, Fox, David J. , Frandsen, Brad, Gelernt, M., Hall, Cassandra L. , Hotchkiss, David R. , Ip, J., Jaffrani, Naseem, Kazmierski, John F., Waxman, F., Kneller, G. Larsen, Labroo, Ajay, Jaffe, Bernard M., Lebenthal, Mark, Lillestol, Michael, Leclerc, Kenneth M. , Maccaro, Paul, Mayer, Nolan, Kozłowski, J , Benjamin, Sanford P., Detweiler, Robert, Igic, Petar, Jackson, Tatum, Pappas, Janine, Littlefield, Ryan , Frey, Anna , Vranian, Robert B., Long, W., Grena, Paul, Arouni, Amy , Quinn, John , Blonder, Ronald, Snyder, H., Slabic, S., Cohen, Kenneth D., Walthall, W. W., Snoddy, Brian, Alvarado, Olga Franco, Leach, Corinne L., Rothman, Steven A., Olatidoye, Abiodun G, Almahameed, Soufian , Rosenthal, Shelly, Reiter, William M., Thompson, T., Thew, Stephen, Kobayashi, Junji , Williams, M., Kramer, Joel H. , Latif, Sidrah , Rhee, B., Ruiz-Serrano, D., Stringam, Stanley, Wolok, K., Focil, Augusto, Butman, Samuel, Ingersoll, Henry, Borge, R. P., Al-Saghir, Y., Farris, Neil, Shore, Karen, Gornick, C., Eilat, P., Paliwal, Y., Mitra, Rito , Jingo, Ahmad, Aslam, Asma , Watson, Robert, Voyce, Stephen , Turakhia, Mintu P. , Goytia-Leos, D., Lurie, Miriam, Mallis, G., Strobel, John, Fisher, D M, Atieh, Mutaz I., Drabick, Andrew, Harman, Ece, Ashcraft, B., Krista, M., Videlefsky, A., Zayas, E. Rivera, Tan, A.E., Gersh, Bernard J , Turakhia, Mintu P , Steinberg, Benjamin A. , Allen, Larry A. , Chan, Paul S. , Freeman, James V. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Mendelson, R., AL-NAHHAS, ADIL M. , Padanilam, B., Pan, D., Raffetto, J., Roan, P., Sackett, M., Seymour, Z., Shoemaker, J. Kevin , Simms, V., Tak, T., Riley, E., Weinstein, D., Hayward, D., Burns, R., Spiller, D., McGarvey, J., Guthrie, R., Flood, R., Aggarwal, R., Jacobs, G., Alfieri, A., Bacon, J., Berger, P., Berry, J., Bloom, S., Kapadia, S., Casanova, R., Christensen, T., Fox, D., Gill, S., Grubb, Søren , Hall, C., Harris, H., Hotchkiss, D., Jones, A., Lee, David S. , Kozlowski, J., Benjamin, S., Detweiler, R., Jackson, T., Littlefield, R., Long, W., Quinn, J., Browne, Kevin D. , Forman, Steven L. , Ebinger, Martin , Williams, David Michael , Stein, R., Kirkland, S., Cohen, K., Walthall, W., Davis, Keith L. , Alvarado, O., Leach, C., Sharma, Anand , Sutter, G., Reiter, W., Kobayashi, J., Kramer, J., Latif, S.A., Adler, Alma J , Butman, Samuel M. , Coats, Paul , Shore, K., Schwartz, M.B., Quinlan, E., Mitra, R., Aslam, A.A., Lurie, M., Atwater, Brett D. , Murray, John M. , Fisher, D., Landes, Reid D. , Harman, E., Zayas, E. Rivera

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 16, 2020 | Volume: 13 | Issue: 5 | Pages: No page available

10.1161/circep.119.007775 | PMID 32298144 Get It

Background: Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. Methods: We assessed factors associated with a 1-year increase in the Atrial Fibrillation Effect on Quality-of-Life score of 1 SD (≥18 points; 3× clinically important difference), among outpatients in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation I registry. Results: Overall, 28% (181/636) of patients had such a hrQoL improvement. Compared with patients not showing large hrQoL improvement, they were of similar age (median 73 versus 74, P =0.3), equally likely to be female (44% versus 48%, P =0.3), but more likely to have newly diagnosed AF at baseline (18% versus 8%; P =0.0004), prior antiarrhythmic drug use (52% versus 40%, P =0.005), baseline antiarrhythmic drug use (34.8% versus 26.8%, P =0.045), and more likely to undergo AF-related procedures during follow-up (AF ablation: 6.6% versus 2.0%, P =0.003; cardioversion: 12.2% versus 5.9%, P =0.008). In multivariable analysis, a history of alcohol abuse (adjusted OR, 2.41; P =0.01) and increased baseline diastolic blood pressure (adjusted OR, 1.23 per 10-point increase and >65 mm Hg; P =0.04) were associated with large improvements in hrQoL at 1 year, whereas patients with prior stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial disease were less likely to improve ( P <0.05 for each). Conclusions: In this national registry of patients with AF, potentially treatable AF risk factors are associated with large hrQoL improvement, whereas less reversible conditions appeared negatively associated with hrQoL improvement. Understanding which patients are most likely to have large hrQoL improvement may facilitate targeting interventions for high-value care that optimizes patient-reported outcomes in AF. Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Nebulized Delivery of Albuterol during Exercise is Safe and Effective in Individuals with Cystic Fibrosis, but does not Augment Bronchodilation or Drug Delivery
Miller, Andrew D. , Baker, Sarah E. , Miller, Andrew D., Reid, Joel M. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | April 16, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.01991 Get It

Objective Exercise is a cornerstone of therapeutic intervention for individuals with cystic fibrosis (CF). However, daily breathing treatments (e.g. chest physiotherapy and inhalation of nebulized albuterol) typically last ~90 minutes, providing a time‐barrier to completing daily exercise. Thus, the purpose of our study was to determine the effects of a combination therapy (exercise and nebulized albuterol) on airway function and bronchodilator delivery. We tested the hypotheses that combination therapy (exercise + nebulized albuterol) would 1) augment the bronchodilator effect compared to either intervention alone, and 2) increase the plasma concentration of albuterol compared to nebulized albuterol alone. Methods Participants with CF (n=9, 5 female, 25±2yrs, forced expiratory volume in 1 second (FEV 1 ) =82±5%predicted) first completed a screening visit (V̇O 2max test, cycle ergometer) and then three study visits in a randomized order. During each study visit, participants completed measures of airway function [FEV 1 and forced expiratory flow from 25–75% of forced vital capacity (FEF 25–75 )], and a blood draw (n=8) to determine plasma albuterol concentration. Participants then completed one of three interventions [albuterol only, (A): 2.5mg nebulized albuterol over 15min; exercise only (E): 30min cycling exercise at 50% of peak watts; albuterol and exercise (A+E): 30min cycling exercise at 50% of peak watts with 2.5mg nebulized albuterol nebulized over the last 15min of cycling). Airway function and plasma albuterol were measured at 0, 15, 30, 45, 60, 90, 120, 180, and 240min after the intervention. Additional plasma albuterol measures were taken 5, and 6hrs post intervention. Data are mean±SD. Results Delivery of nebulized albuterol during exercise did not augment or prolong the bronchodilator effect compared to exercise or albuterol alone. The transient improvement in airway function during the interventions—increase in FEV 1 (time=0.050, intervention p=0.166, interaction p=0.135) or increase in FEF 25–75 (time p=0.001, intervention p=0.207, interaction p=0.990) — was not different between the three interventions. Delivery of nebulized albuterol during exercise did not increase the plasma concentration of albuterol compared to nebulized albuterol alone. The maximum plasma concentration of albuterol (C max ) and the area under the curve (AUC) of albuterol concentration over time were not different between interventions (C max = 2.57±1.60 vs. 2.56±1.13ng·mL −1 , p=0.982; AUC 0–6hrs = 6.1±3.6 vs. 6.9±3.3hr·ng·mL −1 , p=0.188; A vs. A+E interventions, respectively). Conclusions Delivery of nebulized albuterol during moderate intensity exercise did not significantly alter bronchodilator effects or plasma levels of albuterol compared to albuterol or exercise alone. These data suggest that delivery of nebulized albuterol during exercise is safe and effective, but does not augment bronchodilator effects or drug delivery. This combination intervention (A+E) may be a time efficient method for individuals with cystic fibrosis to gain therapeutic effects of exercise and breathing treatments. Support or Funding Information F32 HL131151, Cystic Fibrosis Research Inc.
Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care*
Rayes, Hamza, Subat, Yosuf W., Weister, Timothy J. , Johnson, Madeline Q., Hanson, Andrew C. , Schulte, Phillip J. , Trivedi, Vrinda, Gajić, Ognjen, Rayes, Hamza A, Weister, Timothy, Hanson, Andrew, Gajic, Ognjen , Warner, Matthew A.

Mayo Clinic

Critical Care Medicine | April 16, 2020 | Volume: 48 | Issue: 7 | Pages: 985-992

10.1097/ccm.0000000000004350 | PMID 32304413 Get It

Objectives: Critically ill surgical patients may receive concomitant aspirin and therapeutic anticoagulation postoperatively, yet the safety of this practice remains unknown. We evaluated the risk of major bleeding with concomitant therapy compared with anticoagulation alone. Design: Observational cohort study. Inverse probability of treatment weighting was used to assess the association between concomitant therapy and a primary outcome of major bleeding. Setting: Postoperative ICUs at an academic medical center. Patients: Adults (≥ 18 yr old) receiving anticoagulation during postoperative ICU admission between 2007 and 2016. Interventions: None. Measurements and Main Results: Nine thousand five hundred eighteen anticoagulated patients were included, including 3,237 (34%) receiving aspirin. A total of 1,874 unique patients (19.7%) experienced a major bleeding event. In inverse probability of treatment weighting analyses, concomitant therapy was associated with increased odds for major bleeding (odds ratio, 1.20; 95% CI, 1.05–1.36; p = 0.006) compared with anticoagulation alone. An interaction test suggested a differential relationship between aspirin use and major bleeding based on aspirin use in the 7 days prior to anticoagulation, such that a strong association between aspirin and major bleeding was observed for recent initiators of aspirin (1.40; 1.13–1.72;p = 0.002) but not for those continuing prior aspirin use. Aspirin use prior to anticoagulation did not modify the relationship between concomitant therapy and new myocardial infarction or stroke (i.e., rates were not increased with aspirin discontinuation prior to anticoagulation). Conclusions: Concomitant aspirin and anticoagulation in critically ill surgical patients was associated with an increased rate of major bleeding. Future investigations are warranted to further define optimal management of antiplatelet therapy during anticoagulation in surgical patients.
Last Word on Viewpoint: Physiology and fast marathons
Hunter, Sandra K. , Jones, Andrew M. , Hunter, Sandra K , Jones, Andrew M , Joyner, Michael J. , Lucía, Alejandro

Mayo Clinic

Journal of Applied Physiology | April 15, 2020 | Volume: 128 | Issue: 4 | Pages: 1086-1087

10.1152/japplphysiol.00181.2020 | PMID 32293918 Get It

Advances in the diagnosis of fungal pneumonias
Kelly, Bryan T. , Pennington, Kelly M. , Kelly, Bryan T., Limper, Andrew H.

Mayo Clinic

Expert Review of Respiratory Medicine | April 15, 2020 | Volume: 14 | Issue: 7 | Pages: 703-714

10.1080/17476348.2020.1753506 | PMID 32290725 Get It

Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals
Levine, Deborah A. , Gross, Alden L. , Briceño, Emily M. , Tilton, Nicholas , Kabeto, Mohammed U. , Hingtgen, Stephanie, Giordani, Bruno , Sussman, Jeremy B. , Hayward, Rodney A. , Burke, James , Elkind, Mitchell S.V. , Kulick, Erin R. , Yano, Yuichiro , Gaskin, Darrell J. , Sidney, Stephen , Yaffe, Kristine , Sacco, Ralph L., Roger, Véronique L. , Allen, Norrina B. , Gałecki, Andrzej T. , Tilton, Nicholas, Manly, Jennifer J. , Moran, Andrew Edward , Gottesman, Rebecca F. , Walker, Keenan A. , Wright, Clinton B.

Mayo Clinic

JAMA Neurology | April 13, 2020 | Volume: 77 | Issue: 7 | Pages: 810

10.1001/jamaneurol.2020.0568 | PMID 32282019 Get It

Importance Black individuals are more likely than white individuals to develop dementia. Whether higher blood pressure (BP) levels in black individuals explain differences between black and white individuals in dementia risk is uncertain. Objective To determine whether cumulative BP levels explain racial differences in cognitive decline. Design, Setting, and Participants Individual participant data from 5 cohorts (January 1971 to December 2017) were pooled from the Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, Cardiovascular Health Study, Framingham Offspring Study, and Northern Manhattan Study. Outcomes were standardized as t scores (mean [SD], 50 [10]); a 1-point difference represented a 0.1-SD difference in cognition. The median (interquartile range) follow-up was 12.4 (5.9-21.0) years. Analysis began September 2018. Main Outcomes and Measures The primary outcome was change in global cognition, and secondary outcomes were change in memory and executive function. Exposures Race (black vs white). Results Among 34 349 participants, 19 378 individuals who were free of stroke and dementia and had longitudinal BP, cognitive, and covariate data were included in the analysis. The mean (SD) age at first cognitive assessment was 59.8 (10.4) years and ranged from 5 to 95 years. Of 19 378 individuals, 10 724 (55.3%) were female and 15 526 (80.1%) were white. Compared with white individuals, black individuals had significantly faster declines in global cognition (−0.03 points per year faster [95% CI, −0.05 to −0.01]; P = .004) and memory (−0.08 points per year faster [95% CI, −0.11 to −0.06]; P &amp;lt; .001) but significantly slower declines in executive function (0.09 points per year slower [95% CI, 0.08-0.10]; P &amp;lt; .001). Time-dependent cumulative mean systolic BP level was associated with significantly faster declines in global cognition (−0.018 points per year faster per each 10–mm Hg increase [95% CI, −0.023 to −0.014]; P &amp;lt; .001), memory (−0.028 points per year faster per each 10–mm Hg increase [95% CI, −0.035 to −0.021]; P &amp;lt; .001), and executive function (−0.01 points per year faster per each 10–mm Hg increase [95% CI, −0.014 to −0.007]; P &amp;lt; .001). After adjusting for cumulative mean systolic BP, differences between black and white individuals in cognitive slopes were attenuated for global cognition (−0.01 points per year [95% CI, −0.03 to 0.01]; P = .56) and memory (−0.06 points per year [95% CI, −0.08 to −0.03]; P &amp;lt; .001) but not executive function (0.10 points per year [95% CI, 0.09-0.11]; P &amp;lt; .001). Conclusions and Relevance These results suggest that black individuals’ higher cumulative BP levels may contribute to racial differences in later-life cognitive decline.
Key Components of ICU Recovery Programs: What Did Patients Report Provided Benefit?
McPeake, Joanne , Hibbert, Elizabeth , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Meyer, Joel , Montgomery-Yates, Ashley , Quasim, Tara , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , Sevin, Carla M. , Boehm, Leanne M. , Mikkelsen, Mark E. , Haines, Kimberley

Mayo Clinic

Critical Care Explorations | April 10, 2020 | Volume: 2 | Issue: 4 | Pages: e0088

10.1097/cce.0000000000000088 | PMID 32426730 Get It

Objectives: To understand from the perspective of patients who did, and did not attend ICU recovery programs, what were the most important components of successful programs and how should they be organized. Design: International, qualitative study. Setting: Fourteen hospitals in the United States, United Kingdom, and Australia. Patients: We conducted 66 semi-structured interviews with a diverse group of patients, 52 of whom had used an ICU recovery program and 14 whom had not. Interventions: None. Measurements and Main Results: Using content analysis, prevalent themes were documented to understand what improved their outcomes. Contrasting quotes from patients who had not received certain aspects of care were used to identify perceived differential effectiveness. Successful ICU recovery programs had five key components: 1) Continuity of care; 2) Improving symptom status; 3) Normalization and expectation management; 4) Internal and external validation of progress; and 5) Reducing feelings of guilt and helplessness. The delivery of care which achieved these goals was facilitated by early involvement (even before hospital discharge), direct involvement of ICU staff, and a focus on integration across traditional disease, symptom, and social welfare needs. Conclusions: In this multicenter study, conducted across three continents, patients identified specific and reproducible modes of benefit derived from ICU recovery programs, which could be the target of future intervention refinement.
How to Safely Perform Magnetic Resonance Imaging-guided Radioactive Seed Localizations in the Breast
Lee, Christine U. , Bhatt, Asha A. , Felmlee, Joel P. , Trester, Pamela S. , Lanners, Diana M, Paulsen, Andrew, Brunette, Jeffrey J., Bhatt, Asha, Trester, Pamela, Lanners, Diana, Brunette, Jeffrey

Mayo Clinic

Journal of Clinical Imaging Science | April 9, 2020 | Volume: 10 | Issue: No issue available | Pages: 19

10.25259/jcis_11_2020 | PMID 32363081 Get It

When a breast lesion is seen on only magnetic resonance imaging (MRI) and needs to be excised, pre-operative MRI-guided radioactive seed localization (RSL) is preferred. However, MRI safety and radiation safety issues associated with the inability to recover a potentially lost seed in the MRI scanner room (Zone IV) have precluded this in the past. This manuscript provides a protocol for MRI-guided RSLs that meets MRI safety and radiation safety criteria established by the American College of Radiology and the Nuclear Regulatory Commission. To the authors’ best knowledge, this has never been published in the literature. The complete protocol is provided.
Congenital myasthenic syndrome–associated agrin variants affect clustering of acetylcholine receptors in a domain-specific manner
Shen, Xin‐Ming , Selcen, Duygu , Nazim, Mohammad , Bril, Vera , Tarnopolsky, Mark A. , Brady, Lauren , Fukami, Sae, Amato, Anthony A. , Yiş, Uluç , Engel, Andrew G. , Shen, XinMing, Tarnopolsky, Mark , Ohkawara, Bisei , Ohno, Kinji

Mayo Clinic

JCI Insight | April 8, 2020 | Volume: 5 | Issue: 7 | Pages: No page available

10.1172/jci.insight.132023 | PMID 32271162 Get It

Congenital myasthenic syndromes (CMS) are caused by mutations in molecules expressed at the neuromuscular junction. We report clinical, structural, ultrastructural, and electrophysiologic features of 4 CMS patients with 6 heteroallelic variants in AGRN , encoding agrin. One was a 7.9-kb deletion involving the N-terminal laminin–binding domain. Another, c.4744G>A — at the last nucleotide of exon 26 — caused skipping of exon 26. Four missense mutations (p.S1180L, p.R1509W, p.G1675S, and p.Y1877D) expressed in conditioned media decreased AChR clusters in C2C12 myotubes. The agrin-enhanced phosphorylation of MuSK was markedly attenuated by p.Y1877D in the LG3 domain and moderately attenuated by p.R1509W in the LG1 domain but not by the other 2 mutations. The p.S1180L mutation in the SEA domain facilitated degradation of secreted agrin. The p.G1675S mutation in the LG2 domain attenuated anchoring of agrin to the sarcolemma by compromising its binding to heparin. Anchoring of agrin with p.R1509W in the LG1 domain was similarly attenuated. Mutations of agrin affect AChR clustering by enhancing agrin degradation or by suppressing MuSK phosphorylation and/or by compromising anchoring of agrin to the sarcolemma of the neuromuscular junction.
Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes
Eckhardt, Brittany, Rowsey, Jennifer L. , Thicke, Brianne S, Fraser, Daniel G., O’Grady, Katherine , Bondar, Olga P., Hines, Jolaine M., Thoreson, Andrew R. , Rakshit, Kuntol, Lagnado, Anthony B. , Passos, João F. , Matveyenko, Aleksey V. , Farr, Joshua N. , Passos, João F , Singh, Ravinder , Vella, Adrian , Khosla, Sundeep , Monroe, David G.

Mayo Clinic

JCI Insight | April 8, 2020 | Volume: 5 | Issue: 9 | Pages: No page available

10.1172/jci.insight.135236 | PMID 32267250 Get It

The worldwide prevalence of type 2 diabetes (T2D) is increasing. Despite normal to higher bone density, patients with T2D paradoxically have elevated fracture risk resulting, in part, from poor bone quality. Advanced glycation endproducts (AGEs) and inflammation as a consequence of enhanced receptor for AGE (RAGE) signaling are hypothesized culprits, although the exact mechanisms underlying skeletal dysfunction in T2D are unclear. Lack of inducible models that permit environmental (in obesity) and temporal (after skeletal maturity) control of T2D onset has hampered progress. Here, we show in C57BL/6 mice that a onetime pharmacological intervention (streptozotocin, STZ) initiated in adulthood combined with high-fat diet–induced (HFD-induced) obesity caused hallmark features of human adult-onset T2D, including prolonged hyperglycemia, insulin resistance, and pancreatic β cell dysfunction, but not complete destruction. In addition, HFD/STZ (i.e., T2D) resulted in several changes in bone quality that closely mirror those observed in humans, including compromised bone microarchitecture, reduced biomechanical strength, impaired bone material properties, altered bone turnover, and elevated levels of the AGE CML in bone and blood. Furthermore, T2D led to the premature accumulation of senescent osteocytes with a unique proinflammatory signature. These findings highlight the RAGE pathway and senescent cells as potential targets to treat diabetic skeletal fragility.